4.7 Article

Association Between Major Depressive Episodes in Patients With Chronic Kidney Disease and Initiation of Dialysis, Hospitalization, or Death

期刊

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
卷 303, 期 19, 页码 1946-1953

出版社

AMER MEDICAL ASSOC
DOI: 10.1001/jama.2010.619

关键词

-

资金

  1. Advanced Neuromodulation Systems
  2. AstraZeneca
  3. Best Practice Project Management
  4. Bristol-Myers Squibb/Otsuka
  5. Cyberonics Inc
  6. Forest Pharmaceuticals
  7. Gerson Lehrman Group
  8. GlaxoSmithKline
  9. Jazz Pharmaceuticals
  10. Magellan Health Services
  11. Merck Company
  12. Neuronetics
  13. Novartis Pharmaceuticals
  14. Ono Pharmaceuticals
  15. Organon
  16. Otsuka Pharmaceuticals
  17. Pamlab
  18. Pfizer
  19. Transcept Pharmaceuticals
  20. Urban Institute
  21. Wyeth Ayerst
  22. Forest Laboratories
  23. National Institute of Mental Health
  24. Stanley Medical Research Institute
  25. Veterans Integrated Systems Network 17
  26. VA North Texas Health Care System Research Corporation
  27. National Institutes of Health [2K24DK002818-0]
  28. Rosewood Corporation Chair in Biomedical Science
  29. [P30DK079328]

向作者/读者索取更多资源

Context Patients with chronic kidney disease (CKD) experience increased rates of hospitalization and death. Depressive disorders are associated with morbidity and mortality. Whether depression contributes to poor outcomes in patients with CKD not receiving dialysis is unknown. Objective To determine whether the presence of a current major depressive episode (MDE) is associated with poorer outcomes in patients with CKD. Design, Setting, and Patients Prospective cohort study of 267 consecutively recruited outpatients with CKD (stages 2-5 and who were not receiving dialysis) at a VA medical center between May 2005 and November 2006 and followed up for 1 year. An MDE was diagnosed by blinded personnel using the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) criteria. Main Outcome Measures The primary outcome was event-free survival defined as the composite of death, dialysis initiation, or hospitalization. Secondary outcomes included each of these events assessed separately. Results Among 267 patients, 56 had a current MDE (21%) and 211 did not (79%). There were 127 composite events, 116 hospitalizations, 38 dialysis initiations, and 18 deaths. Events occurred more often in patients with an MDE compared with those without an MDE (61% vs 44%, respectively, P=.03). Four patients with missing dates of hospitalization were excluded from survival analyses. The mean (SD) time to the composite event was 206.5 (19.8) days (95% CI, 167.7-245.3 days) for those with an MDE compared with 273.3 (8.5) days (95% CI, 256.6-290.0 days) for those without an MDE (P=.003). The adjusted hazard ratio (HR) for the composite event for patients with an MDE was 1.86 (95% CI, 1.23-2.84). An MDE at baseline independently predicted progression to dialysis (HR, 3.51; 95% CI, 1.77-6.97) and hospitalization (HR, 1.90; 95% CI, 1.23-2.95). Conclusion The presence of an MDE was associated with an increased risk of poor outcomes in CKD patients who were not receiving dialysis, independent of comorbidities and kidney disease severity. JAMA. 2010; 303(19): 1946-1953

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据